Literature DB >> 17088980

Establishment of three malignant peripheral nerve sheath tumor cell lines, FU-SFT8611, 8710 and 9817: conventional and molecular cytogenetic characterization.

Mikiko Aoki1, Kazuki Nabeshima, Jun Nishio, Masako Ishiguro, Chikako Fujita, Kaori Koga, Makoto Hamasaki, Yasuhiko Kaneko, Hiroshi Iwasaki.   

Abstract

Malignant peripheral nerve sheath tumor (MPNST) is a rare malignant tumor, for which only a few cultured cell lines are available to date. In the present study, we established three new MPNST cell lines, FU-SFT8611, FU-SFT8710 and FU-SFT9817, from a 40-year-old Japanese man without neurofibromatosis 1 (NF1), a 43-year-old Japanese woman with NF1, and a 61-year-old Japanese woman without NF1, respectively. These cell lines were in culture for more than 3 years in vitro, and exhibit complex karyotypes lacking a common characteristic pattern. Two of the cell lines, FU-SFT8611 and FU-SFT9817, were tumorigenic in nude mice, with the resultant tumors showing an immunohistochemical phenotype similar to the original tumors. Comparative genomic hybridization analysis revealed that chromosomal imbalances were very similar between the original tumors and the established cell lines, but no consistent imbalances among the three cell lines as reported so far. As for chromosomal imbalances that have been reported to be associated with poor survival, FU-SFT8611 exhibited a gain of chromosome 17q22-qter, and FU-SFT9817 showed a loss of 17q22-qter, while gains of 17q24 and 7p15-p21 were observed in none of the cell lines. These newly established cell lines provide a valuable resource for biological and pathological investigations into new treatment regimes for MPNST.

Entities:  

Mesh:

Year:  2006        PMID: 17088980     DOI: 10.3892/ijo.29.6.1421

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2.

Authors:  Michiyuki Hakozaki; Hiroshi Hojo; Michiko Sato; Takahiro Tajino; Hitoshi Yamada; Shinichi Kikuchi; Masafumi Abe
Journal:  Virchows Arch       Date:  2009-11-18       Impact factor: 4.064

2.  Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumor.

Authors:  Suguru Fukushima; Makoto Endo; Yoshihiro Matsumoto; Jun-Ichi Fukushi; Tomoya Matsunobu; Ken-Ichi Kawaguchi; Nokitaka Setsu; Keiichiro IIda; Nobuhiko Yokoyama; Makoto Nakagawa; Kenichiro Yahiro; Yoshinao Oda; Yukihide Iwamoto; Yasuharu Nakashima
Journal:  PLoS One       Date:  2017-05-30       Impact factor: 3.240

3.  lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma.

Authors:  Hideharu Yamada; Masanobu Takahashi; Munenori Watanuki; Mika Watanabe; Sakura Hiraide; Ken Saijo; Keigo Komine; Chikashi Ishioka
Journal:  Oncol Lett       Date:  2021-04-08       Impact factor: 2.967

4.  BL1391: an established cell line from a human malignant peripheral nerve sheath tumor with unique genomic features.

Authors:  Doron Tolomeo; Antonio Agostini; Gemma Macchia; Alberto L'Abbate; Marco Severgnini; Ingrid Cifola; Maria Antonia Frassanito; Vito Racanelli; Antonio Giovanni Solimando; Felix Haglund; Fredrik Mertens; Clelia Tiziana Storlazzi
Journal:  Hum Cell       Date:  2020-08-27       Impact factor: 4.174

5.  Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivo through suppression of PDGFR-β.

Authors:  Jun Ohishi; Mikiko Aoki; Kazuki Nabeshima; Junji Suzumiya; Tamotsu Takeuchi; Akira Ogose; Michiyuki Hakozaki; Yuichi Yamashita; Hiroshi Iwasaki
Journal:  BMC Cancer       Date:  2013-05-04       Impact factor: 4.430

Review 6.  The Role of Polycomb Repressive Complex in Malignant Peripheral Nerve Sheath Tumor.

Authors:  Xiyuan Zhang; Béga Murray; George Mo; Jack F Shern
Journal:  Genes (Basel)       Date:  2020-03-09       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.